Difference between revisions of "Pazopanib (Votrient)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
m (updated package insert links) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors FGFR-1 and FGFR-3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). Interferes tumor angiogenesis, growth, and cancer progression.<ref name="insert">[https://www.gsksource.com/gskprm/htdocs/documents/VOTRIENT-PI-MG.PDF Pazopanib (Votrient) package insert]</ref><ref>[ | + | Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors FGFR-1 and FGFR-3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). Interferes tumor angiogenesis, growth, and cancer progression.<ref name="insert">[https://www.gsksource.com/gskprm/htdocs/documents/VOTRIENT-PI-MG.PDF Pazopanib (Votrient) package insert]</ref><ref>[[Media:Pazopanib.pdf | Pazopanib (Votrient) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[https://www.gsksource.com/gskprm/htdocs/documents/VOTRIENT-PI-MG.PDF#page=27 Pazopanib (Votrient) package insert PDF pages 27-32]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/pazopanib.asp Pazopanib (Votrient) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/pazopanib.asp Pazopanib (Votrient) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/pazopanib.asp Pazopanib (Votrient) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/pazopanib.asp Pazopanib (Votrient) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/pazopanib-patient-drug-information Pazopanib (Votrient) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pazopanib-patient-drug-information Pazopanib (Votrient) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/pazopanib-patient-drug-information Pazopanib (Votrient) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pazopanib-patient-drug-information Pazopanib (Votrient) patient drug information (UpToDate)]</ref> | ||
Revision as of 21:11, 22 July 2012
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors FGFR-1 and FGFR-3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). Interferes tumor angiogenesis, growth, and cancer progression.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Pazopanib (Votrient) package insert PDF pages 27-32[1]
- Pazopanib (Votrient) patient drug information (Chemocare)[3]
- Pazopanib (Votrient) patient drug information (UpToDate)[4]